ATE171169T1 - Substituierte oxazolidine mit stimulierende wirkung auf beta-adrenergic rezeptoren - Google Patents

Substituierte oxazolidine mit stimulierende wirkung auf beta-adrenergic rezeptoren

Info

Publication number
ATE171169T1
ATE171169T1 AT95901448T AT95901448T ATE171169T1 AT E171169 T1 ATE171169 T1 AT E171169T1 AT 95901448 T AT95901448 T AT 95901448T AT 95901448 T AT95901448 T AT 95901448T AT E171169 T1 ATE171169 T1 AT E171169T1
Authority
AT
Austria
Prior art keywords
pct
beta
adrenergic receptors
stimulating effect
date jun
Prior art date
Application number
AT95901448T
Other languages
English (en)
Inventor
Alfred Sallmann
Hans-Peter Gschwind
Eric Francotte
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE171169T1 publication Critical patent/ATE171169T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95901448T 1993-12-10 1994-11-28 Substituierte oxazolidine mit stimulierende wirkung auf beta-adrenergic rezeptoren ATE171169T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH369193 1993-12-10

Publications (1)

Publication Number Publication Date
ATE171169T1 true ATE171169T1 (de) 1998-10-15

Family

ID=4261454

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95901448T ATE171169T1 (de) 1993-12-10 1994-11-28 Substituierte oxazolidine mit stimulierende wirkung auf beta-adrenergic rezeptoren

Country Status (14)

Country Link
US (1) US5635524A (de)
EP (1) EP0733047B1 (de)
JP (1) JP3792713B2 (de)
KR (1) KR100354528B1 (de)
AT (1) ATE171169T1 (de)
AU (1) AU692809B2 (de)
CA (1) CA2177171C (de)
DE (1) DE69413417T2 (de)
ES (1) ES2121621T3 (de)
FI (1) FI119987B (de)
HU (1) HU221500B (de)
NO (1) NO306463B1 (de)
NZ (1) NZ276421A (de)
WO (1) WO1995015953A1 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064257A (en) * 1976-07-19 1977-12-20 Syntex (U.S.A.) Inc. Thiazole cardiovascular agents
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
TW209832B (de) * 1989-10-10 1993-07-21 Glaxo Group Ltd

Also Published As

Publication number Publication date
WO1995015953A1 (en) 1995-06-15
US5635524A (en) 1997-06-03
JP3792713B2 (ja) 2006-07-05
AU692809B2 (en) 1998-06-18
CA2177171C (en) 2006-01-17
NO962424L (no) 1996-06-07
HU221500B (en) 2002-10-28
EP0733047A1 (de) 1996-09-25
KR100354528B1 (ko) 2002-12-18
DE69413417T2 (de) 1999-03-04
FI962341A0 (fi) 1996-06-05
NO962424D0 (no) 1996-06-07
ES2121621T3 (es) 1998-12-01
EP0733047B1 (de) 1998-09-16
NO306463B1 (no) 1999-11-08
HU9601585D0 (en) 1996-08-28
HUT74689A (en) 1997-01-28
CA2177171A1 (en) 1995-06-15
FI119987B (fi) 2009-05-29
NZ276421A (en) 1998-01-26
DE69413417D1 (de) 1998-10-22
AU1068395A (en) 1995-06-27
FI962341A (fi) 1996-06-05
JPH09506357A (ja) 1997-06-24

Similar Documents

Publication Publication Date Title
KR970704435A (ko) 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands)
ATE181731T1 (de) Isothioharnstoff-derivate als no synthase hemmer
BR9507677A (pt) Composto composição farmacéutica processo para a profilaxia ou para o tratamento de condições associadas à inflamação à artrite ou à dor em um mamifero uso do composto processo para a preparação do composto e novo intermediário
FR2549049B1 (fr) Nouvelles amidines, leur procede de preparation et leur application therapeutique
DE69525327T2 (de) Anthracyclin-derivate
DE69512208T2 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
ATE171169T1 (de) Substituierte oxazolidine mit stimulierende wirkung auf beta-adrenergic rezeptoren
ES2121218T3 (es) Fenoxifenilciclopentenilhidroxiureas.
CA2105215A1 (en) Novel oxazolidines
ATE83484T1 (de) 20,21-dinoreburnamenin-derivate, substituiert in position 15 durch eine aminogruppe und deren salze, verfahren zu deren herstellung und die auf diese weise erhaltenen zwischenverbindungen, deren anwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen.
TH148527B (th) อนุพันธ์ไพราโซโล-ควินาโซลีน กระบวนการสำหรับการเตรียมสารนั้นและการใช้สารนั้นเป็นสารยับยั้งไคเนส

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification